Co-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database

Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. This retrospective cross-sectional study aimed to characterise concomitant medication use and explore its associations with GBE utilisation and patient-reported experiences using data from the pharmacoepidemiological database PhytoVIS. Methods: In a study cohort of 184 patients, we examined co-medication use, associations with GBE treatment habits (intake frequency, treatment duration, and daily dosage) and patient-reported perception of effectiveness and tolerability using descriptive statistics and exploratory non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients reporting adverse events (AEs) rated as significant, and patients with GABS scores >2. Results: Overall, 64.7% of patients used co-medication. Cardiovascular drugs were used by 27.7% of all patients, followed by antidiabetic drugs (11.4%) and analgesics/anti-inflammatory drugs (9.8%). While no statistically significant correlation with treatment duration was observed, our exploratory, unadjusted analysis indicated a weak negative correlation between the number of co-medications and daily GBE doses (Spearman’s ρ = −0.156, 95% CI [−0.299, −0.006], p = 0.037). Three patients reported AEs rated as significant during GBE intake. However, patients generally rated perceived effectiveness and tolerability favourably across co-medication groups. Four GBE users had calculated cumulative GABS scores >2 and rated the perceived effectiveness of GBE as moderate to very good without reporting any adverse events. Conclusion: Co-medication was common in GBE users, and patients rated the effectiveness and tolerability favourably across co-medication groups. The weak correlation between a higher number of co-medications and lower GBE doses should be interpreted cautiously as a hypothesis-generating finding. Overall, these findings highlight the relevance of considering concomitant medication when examining GBE utilisation, particularly in the context of self-medication.

Authors

Publication Details

Journal
Neurology International
Published
2026-11-18
DOI
https://doi.org/10.3390/neurolint18110220
Primary Topic
Ginkgo biloba and Cashew Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Co-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database

Ralph Mösges, Annika J. Scholl, Beatrice E. Bachmeier, Svenja Beatrice Frenzel et al.
3 links
Neurology International
Ginkgo biloba and Cashew Applications
article

Co-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database

Ralph Mösges, Annika J. Scholl, Beatrice E. Bachmeier, Svenja Beatrice Frenzel, Alexandra Drebka, Nele L. Bößneck, Alexander F. Hau, Julie K. Könnecke
article en

Abstract

Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. This retrospective cross-sectional study aimed to characterise concomitant medication use and explore its associations with GBE utilisation and patient-reported experiences using data from the pharmacoepidemiological database PhytoVIS. Methods: In a study cohort of 184 patients, we examined co-medication use, associations with GBE treatment habits (intake frequency, treatment duration, and daily dosage) and patient-reported perception of effectiveness and tolerability using descriptive statistics and exploratory non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients reporting adverse events (AEs) rated as significant, and patients with GABS scores >2. Results: Overall, 64.7% of patients used co-medication. Cardiovascular drugs were used by 27.7% of all patients, followed by antidiabetic drugs (11.4%) and analgesics/anti-inflammatory drugs (9.8%). While no statistically significant correlation with treatment duration was observed, our exploratory, unadjusted analysis indicated a weak negative correlation between the number of co-medications and daily GBE doses (Spearman’s ρ = −0.156, 95% CI [−0.299, −0.006], p = 0.037). Three patients reported AEs rated as significant during GBE intake. However, patients generally rated perceived effectiveness and tolerability favourably across co-medication groups. Four GBE users had calculated cumulative GABS scores >2 and rated the perceived effectiveness of GBE as moderate to very good without reporting any adverse events. Conclusion: Co-medication was common in GBE users, and patients rated the effectiveness and tolerability favourably across co-medication groups. The weak correlation between a higher number of co-medications and lower GBE doses should be interpreted cautiously as a hypothesis-generating finding. Overall, these findings highlight the relevance of considering concomitant medication when examining GBE utilisation, particularly in the context of self-medication.

Neurology InternationalVol. 18(11)
Dr. Willmar Schwabe
Good health and well-being
Ginkgo biloba and Cashew Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon